|
1
|
Hlaváč V, Brynychová V, Václavíková R,
Ehrlichová M, Vrána D, Pecha V, Koževnikovová R, Trnková M, Gatěk
J, Kopperová D, et al: The expression profile of ATP-binding
cassette transporter genes in breast carcinoma. Pharmacogenomics.
14:515–529. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gottesman MM, Hrycyna CA, Schoenlein PV,
Germann UA and Pastan I: Genetic analysis of the multidrug
transporter. Annu Rev Genet. 29:607–649. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lo YL and Liu Y: Reversing multidrug
resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and
BCL-2/BCL-xL using liposomal antisense oligonucleotides. PLoS One.
9:e901802014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deeley RG, Westlake C and Cole SP:
Transmembrane transport of endo- and xenobiotics by mammalian
ATP-binding cassette multidrug resistance proteins. Physiol Rev.
86:849–899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krishnamurthy P and Schuetz JD: Role of
ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol.
46:381–410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gong MQ, Wu JL, Chen B, Zhuo RX and Cheng
SX: Self-assembled polymer/inorganic hybrid nanovesicles for
multiple drug delivery to overcome drug resistance in cancer
chemotherapy. Langmuir. 31:5115–5122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bao L, Hazari S, Mehra S, Kaushal D, Moroz
K and Dash S: Increased expression of P-glycoprotein and
doxorubicin chemoresistance of metastatic breast cancer is
regulated by miR-298. Am J Pathol. 180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger W, Hauptmann E, Elbling L,
Vetterlein M, Kokoschka EM and Micksche M: Possible role of the
multidrug resistance-associated protein (MRP) in chemoresistance of
human melanoma cells. Int J Cancer. 71:108–115. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Padmanabhan R, Chen KG, Gillet JP, Handley
M, Mallon BS, Hamilton RS, Park K, Varma S, Mehaffey MG, Robey PG,
et al: Regulation and expression of the ATP-binding cassette
transporter ABCG2 in human embryonic stem cells. Stem Cells.
30:2175–2187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pogribny IP, Filkowski JN, Tryndyak VP,
Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs
and their targets are associated with acquired resistance of MCF-7
breast cancer cells to cisplatin. Int J Cancer. 127:1785–1794.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silvera D, Formenti SC and Schneider RJ:
Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li BD, McDonald JC, Nassar R and De
Benedetti A: Clinical outcome in stage I to III breast carcinoma
and eIF4E overexpression. Ann Surg. 227:756–761; 761–763. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demosthenous C, Han JJ, Stenson MJ, Maurer
MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T and
Gupta M: Translation initiation complex eIF4F is a therapeutic
target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Oncotarget. 6:9488–9501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fan S, Li Y, Yue P, Khuri FR and Sun SY:
The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments
TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5
induction independent of inhibition of cap-dependent protein
translation. Neoplasia. 12:346–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
She QB, Halilovic E, Ye Q, Zhen W,
Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key
effector of the oncogenic activation of the AKT and ERK signaling
pathways that integrates their function in tumors. Cancer Cell.
18:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boussemart L, Malka-Mahieu H, Girault I,
Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro
N, Thuaud F, et al: eIF4F is a nexus of resistance to anti-BRAF and
anti-MEK cancer therapies. Nature. 513:105–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karthikeyan S and Hoti SL: Development of
fourth generation ABC inhibitors from natural products: A novel
approach to overcome cancer multidrug resistance. Anticancer Agents
Med Chem. 15:605–615. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ween MP, Armstrong MA, Oehler MK and
Ricciardelli C: The role of ABC transporters in ovarian cancer
progression and chemoresistance. Crit Rev Oncol Hematol.
96:220–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mazan-Mamczarz K, Zhao XF, Dai B,
Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang
Y, Lehrmann E, et al: Down-regulation of eIF4GII by miR-520c-3p
represses diffuse large B cell lymphoma development. PLoS Genet.
10:e10041052014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ho BC, Yu SL, Chen JJ, Chang SY, Yan BS,
Hong QS, Singh S, Kao CL, Chen HY, Su KY, et al:
Enterovirus-induced miR-141 contributes to shutoff of host protein
translation by targeting the translation initiation factor eIF4E.
Cell Host Microbe. 9:58–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma J, Wang T, Guo R, Yang X, Yin J, Yu J,
Xiang Q, Pan X, Tang H and Lei X: Involvement of miR-133a and
miR-326 in ADM resistance of HepG2 through modulating expression of
ABCC1. J Drug Target. 23:519–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Zhao J, Zhang JW, Huang QY, Huang
JZ, Chi LS, Tang HJ, Liu GQ, Zhu DJ and Ma WM: MicroRNA-217,
down-regulated in clear cell renal cell carcinoma and associated
with lower survival, suppresses cell proliferation and migration.
Neoplasma. 60:511–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang H, Zhang P, Xiang Q, Yin J, Yu J,
Yang X and Lei X: Let-7 g microRNA sensitizes
fluorouracil-resistant human hepatoma cells. Pharmazie. 69:287–292.
2014.PubMed/NCBI
|
|
31
|
Borel F, Han R, Visser A, Petry H, van
Deventer SJ, Jansen PL and Konstantinova P: Réseau Centre de
Ressources Biologiques Foie (French Liver Biobanks Network),
France: Adenosine triphosphate-binding cassette transporter genes
up-regulation in untreated hepatocellular carcinoma is mediated by
cellular microRNAs. Hepatology. 55:821–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z,
Liu J, Cui Y, Bian X, Bie P and Qian C: MicroRNA-122 sensitizes HCC
cancer cells to adriamycin and vincristine through modulating
expression of MDR and inducing cell cycle arrest. Cancer Lett.
310:160–169. 2011.PubMed/NCBI
|
